CapsoVision, Inc. (CV)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.99+0.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance the second-generation CapsoCam Colon product with 510(k) submission and ongoing clinical studies including pancreatic cancer detection.
Stated as a priority in 2 of last 2 quarters. Management reported the CapsoCam Colon 510(k) submission timing moved from Q3 2026 in 2026-Q1 to Q4 2026 in 2026-Q2, with ongoing clinical enrollment for pancreatic cancer detection. The pipeline progress is consistent with management's stated development timeline, indicating delivery on this product advancement priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not enough signal yet.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Pipeline continues to advance with CapsoCam Colon on track for 510(k) submission in Q4 2026, with ongoing enrollment in pancreatic cancer detection study.”
“Pipeline programs progressing as planned, including second-generation CapsoCam Colon with 510(k) submission expected in Q3 2026 and pancreatic cancer study initiated.”
Launch AI-assisted reading feature AI Highlights internationally and anticipate FDA clearance and U.S. launch in late 2026.
Stated as a priority in 2 of last 2 quarters. Management launched AI Highlights commercially in the EU and other markets by 2026-Q2 and anticipates FDA clearance by end of Q3 2026 for U.S. launch. This trajectory matches management's prior guidance and shows progress toward the commercial launch milestone.
“Launched AI Highlights commercially in EU and other international markets; anticipate FDA clearance by end of Q3 2026.”
“AI-assisted reading feature on track for anticipated FDA clearance mid-year, with commercial launch expected shortly thereafter.”
Grow adoption of CapsoCam Plus through increased procedure volume and renewals with major gastrointestinal health systems.
Stated as a priority in 2 of last 2 quarters. Management reported CapsoCam Plus usage increased from 167,000 patients in 2026-Q1 to 176,000 in 2026-Q2, reflecting growing adoption. Key renewals with large GI networks were secured in both quarters, indicating delivery on expanding clinical use and customer retention.
“Continued commercial momentum with expanding adoption across large hospital systems and GI networks, including key customer renewals.”
“Secured key customer renewals with large GI networks, reinforcing platform value and long-term relationships.”
Raise funds via private placement and at-the-market equity offering program to support operations and growth initiatives.
Stated as a priority in 2 of last 2 quarters. Management completed a $14 million private placement in 2026-Q1 and established a $100 million at-the-market equity offering program in 2026-Q2. These capital raises align with management's stated funding strategy to support growth and operations, showing delivery on capital allocation priorities.
“Entered into a sales agreement for an at-the-market equity offering program up to $100 million with Cantor Fitzgerald & Co.”
“Completed a $14 million private placement of public equity financing on March 16, 2026.”
Collaborate with Canon to develop CMOS image sensor samples for next-generation capsule endoscopy products.
Stated as a priority in 2 of last 2 quarters. Management reported ongoing development activities with Canon for CMOS image sensors, reflected in increased R&D expenses in both 2026-Q1 and 2026-Q2. This indicates continued progress on the partnership and product development collaboration.
“Expenses include non-recurring engineering services for the Canon development project.”
“Development of new CMOS image sensors under agreement with Canon Inc. is driving R&D expenses.”
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.